Sirio Pharma Starts to Focus on Innovation

Sirio Pharma believes the pandemic has made consumers more concerned about their health and thus promoted the development of health industry. In Sirio Pharma’s annual result, it is worth noting that the company invested RMB 83,190,300 yuan (USD $12.8 million) for R&D expenses in 2021, with an increase of 28.56% year-on-year. The number of R&D personnel also increased from 269 in 2020 to 318 in 2021, accounting for 12.95% of the total number of employees. Sirio Pharma also submitted 35 invention patent applications and launched several new products, including gelatinized candy, essence tube drinks, and popping beads. By doing so, Sirio Pharma affirmed its two main strategies: innovative technology and internationalization, hoping to become a global leader among nutritional and health food CDMOs. (Source: shuzhengkangxun)

Visit HPA-China’s Information Hub, CLICK HERE